Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma
Continuous high-dose local administration of natural interleukin-2 (nIL-2) is tolerated without side effects in advanced-cancer patients and induces complete remission and local and systemic immunoactivation, as we have shown previously . Those facts support our belief that interleukins should be administered locally, rather than systemically, for effective treatment of carcinoma. Local administration can be expected to induce fewer side effects and to activate tumor-infiltrating immune cells, which are reported to be 100 times more cytotoxic than activated blood cells . The local use of interleukins is also more economical in that it reduces renal loss of small molecules. Although metastatic tumor disease seems not to be suitable for a local approach, the addition of local immunoactivation to systemic treatment might improve the therapeutic effectiveness without increasing toxicity.
KeywordsRenal Cell Carcinoma Bone Metastasis Pulmonary Metastasis Metastatic Renal Cell Carcinoma ECOG Performance Status
Unable to display preview. Download preview PDF.
- 2.Bergmann L, Weidmann E, Mitrou PS, et al. (1990) Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie 13: 137Google Scholar
- 3.Daniele RP (ed) (1988) Immunology and immunologic diseases of the lung. Blackwell Scientific Publ, OxfordGoogle Scholar
- 7.Heinzer H, Huland E, Huland H (1990) Activated eosinophil leukocytes in interleukin-2 (IL-2) treated patients: Evidence for a new antitumor effector mechanism. J Cancer Res Clin Oncol 116 (Suppl I): 369Google Scholar
- 10.Negrier S, Philip T, Stoter G, et al. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 25: 21Google Scholar
- 12.Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 880Google Scholar